Allergan PLC. (NYSE:AGN) has been assigned a $285.00 target price by equities researchers at Royal Bank Of Canada in a research note issued on Thursday. The firm presently has a “buy” rating on the stock. Royal Bank Of Canada’s price objective suggests a potential upside of 17.45% from the company’s previous close.

AGN has been the subject of several other research reports. Cowen and Company set a $400.00 price objective on Allergan PLC. and gave the company a “buy” rating in a report on Thursday, June 8th. Sanford C. Bernstein restated an “outperform” rating on shares of Allergan PLC. in a report on Thursday, May 25th. Mizuho decreased their price objective on Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a report on Friday, June 9th. Cantor Fitzgerald started coverage on Allergan PLC. in a report on Friday, June 16th. They set a “neutral” rating and a $231.00 price objective for the company. Finally, Zacks Investment Research upgraded Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price objective for the company in a report on Tuesday, July 11th. Seven analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $274.14.

Shares of Allergan PLC. (NYSE:AGN) traded down 3.08% during trading on Thursday, hitting $242.65. 3,014,756 shares of the stock traded hands. The firm has a market cap of $81.50 billion, a P/E ratio of 7.56 and a beta of 1.16. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The company has a 50-day moving average of $245.21 and a 200-day moving average of $237.12.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The company’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.35 earnings per share. On average, analysts forecast that Allergan PLC. will post $16.10 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Allergan PLC. (AGN) Given a $285.00 Price Target at Royal Bank Of Canada” was reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/08/06/allergan-plc-agn-given-a-285-00-price-target-at-royal-bank-of-canada.html.

In related news, Director Nesli Basgoz sold 1,889 shares of the company’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.36% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Crestwood Advisors Group LLC acquired a new position in Allergan PLC. during the first quarter valued at $103,000. Feltz Wealth PLAN Inc. acquired a new position in Allergan PLC. during the first quarter valued at $107,000. Enterprise Financial Services Corp boosted its position in Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares in the last quarter. Jacobi Capital Management LLC boosted its position in Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after buying an additional 22 shares in the last quarter. Finally, JNBA Financial Advisors boosted its position in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares in the last quarter. 84.66% of the stock is currently owned by institutional investors and hedge funds.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.